Heparin-Induced Thrombocytopenia (HIT)
Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated complication of heparin therapy characterized by a drop in platelet count and a paradoxically increased risk of dangerous blood clots.
Things worth knowing about "Heparin-Induced Thrombocytopenia"
Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated complication of heparin therapy characterized by a drop in platelet count and a paradoxically increased risk of dangerous blood clots.
What is Heparin-Induced Thrombocytopenia?
Heparin-induced thrombocytopenia (HIT) is a serious, immune-mediated adverse reaction that can occur during treatment with the anticoagulant drug heparin. Despite a significant drop in platelet count, patients paradoxically face an increased risk of thrombosis (blood clot formation) rather than bleeding. HIT is a medical emergency requiring immediate clinical action.
Types of HIT
HIT Type I
HIT Type I is a non-immunological and generally mild form. Platelet counts drop slightly within the first two days of heparin therapy but typically recover on their own, even without discontinuing the medication. This form is considered clinically less significant.
HIT Type II
HIT Type II is the immune-mediated and clinically dangerous form. It typically develops 5 to 14 days after the start of heparin therapy and is associated with a significant drop in platelet count and a high risk of thromboembolic complications. Immediate medical intervention is required.
Causes and Pathophysiology
In HIT Type II, the immune system produces antibodies (mainly of the IgG class) directed against a complex formed by heparin and the endogenous protein platelet factor 4 (PF4). These antibodies massively activate platelets, leading to their consumption while simultaneously triggering excessive coagulation. This results in the paradoxical finding of fewer platelets but a dramatically elevated risk of thrombosis.
- Unfractionated heparin (derived from porcine intestine) carries a higher HIT risk than low-molecular-weight heparin
- Surgical patients are more frequently affected than medical patients
- Women appear to have a slightly higher risk
Symptoms
The clinical presentation of HIT is multifaceted and closely linked to the occurrence of thrombosis:
- Drop in platelet count by more than 50% from baseline
- New thrombotic events in veins or arteries (e.g., deep vein thrombosis, pulmonary embolism, stroke)
- Skin necrosis at the heparin injection site
- Acute systemic reactions shortly after heparin administration (e.g., fever, blood pressure drop, pain)
Diagnosis
Diagnosis of HIT is based on a combination of clinical assessment and laboratory testing:
4T Score
The 4T score is a standardized clinical scoring system that evaluates four criteria: Thrombocytopenia (magnitude of platelet drop), Timing (onset relative to heparin exposure), Thrombosis (presence of new clots), and other causes (exclusion of alternative explanations). A high 4T score raises the probability of HIT.
Laboratory Testing
- ELISA assay: Detection of antibodies against the heparin-PF4 complex
- Functional assays (e.g., serotonin release assay, HIPA test): Confirmation of antibody-mediated platelet activation
- Regular platelet count monitoring during heparin therapy
Treatment
When HIT is strongly suspected, heparin must be stopped immediately -- including all heparin-containing flushes and coated catheters. Alternative anticoagulants that do not trigger the HIT mechanism are used as replacements:
- Argatroban: Direct thrombin inhibitor, preferred in patients with renal impairment
- Fondaparinux: Synthetic pentasaccharide with a low risk of HIT
- Bivalirudin: Direct thrombin inhibitor, frequently used in intensive care settings
- Danaparoid: Heparinoid approved for HIT treatment in several European countries
Oral anticoagulation with vitamin K antagonists (e.g., warfarin) should only be initiated after adequate platelet recovery and under bridging coverage with an alternative anticoagulant, as premature introduction may increase the risk of skin necrosis or gangrene.
Prognosis and Prevention
HIT is associated with significant morbidity and mortality: in untreated cases, up to 50% of patients experience thromboembolic complications. Early recognition and prompt switching of anticoagulation therapy significantly reduce this risk. Patients who have experienced HIT should not receive heparin in the future, and this must be clearly documented in their medical records.
References
- Linkins L.-A. et al. - Treatment and prevention of heparin-induced thrombocytopenia. Chest, 141(2 Suppl):e495S-e530S, 2012. American College of Chest Physicians.
- Greinacher A. - Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 373:252-261, 2015.
- Warkentin T.E. - Heparin-induced thrombocytopenia: pathogenesis and management. British Journal of Haematology, 121(4):535-555, 2003.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryMost read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Heparin-Induced Thrombocytopenia-en